• News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·MX1.AX
Share

Micro-X Limited Stocks

A$ 0.05Last Updated 15.05.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 25.88M

A$ 0.05
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Micro-X Limited designs, develops, and manufactures lightweight carbon nano tube-based X-ray products for the healthcare and security imaging markets in Australia. The company offers rover veterinary, a mobile X-ray machine to diagnose and treat animals for general veterinarian practices; Carestream DRX Revolution Nano, a mobile X-ray imaging machine used for high intensity workflow diagnostic medical imaging in hospitals; and IED X-ray cameras. It also provides miniature baggage scanners to detect hidden threats concealed within passenger carry-on luggage; airport screening reimagined, a passenger self-screening airport checkpoint; and brain CT scanners for use in road and air ambulances. The company was incorporated in 2011 and is based in Tonsley, Australia.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.05.2026 21:00

SpaceX's listing date and rival Nvidia's record: what's important about the IPO by Ma. 17

17.05.2026 18:01

Downgrade game-1789: how a relocant from Geneva made money before the French Revolution

17.05.2026 15:01

Frustration and reward: how to get rid of the tendency to over-trade

16.05.2026 17:18

Main in small-caps: BuzzFeed deal, bets on AI boom, forecast from BNP Paribas AM

16.05.2026 13:01

Highlights of the week: Trump in China, Cerebras IPO, UK crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026